Differential activity and clinical utility of latanoprost in glaucoma and ocular hypertension

QR Code

Differential activity and clinical utility of latanoprost in glaucoma and ocular hypertension

Fernanda Pacella, Paolo Turchetti, Valentina Santamaria, David Impallara, Gianpaolo Smaldone, Chiara Brillante, Aloisa Librando, Angela Damiano,&nbsp;Jose Pecori-Giraldi, Elena PacellaDepartment of Sense Organs, University of Rome &quot;Sapienza&quot;, Roma, ItalyBackground:...

Full description

Saved in:

Bibliographic Details
Main Authors:	Pacella F, Turchetti P, Santamaria V,&nbsp;Impallara D, Smaldone G, Brillante C, Librando A, Damiano A, Pecori-Giraldi J, Pacella E
Format:	article
Language:	EN
Published:	Dove Medical Press 2012
Subjects:	Ophthalmology RE1-994
Online Access:	https://doaj.org/article/f551e94c922c4fd6b03d2c12b01783eb
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Differential pharmacology and clinical utility of preservative-free tafluprost in the treatment of ocular hypertension and glaucoma
by: Ermiş&nbsp;SS
Published: (2012)

Ocular surface disease in patients with glaucoma or ocular hypertension treated with either BAK-preserved latanoprost or BAK-free travoprost
by: Gregory Katz, et al.
Published: (2010)

Latanoprost in the treatment of glaucoma
by: Alm A
Published: (2014)

Efficacy and safety of benzalkonium chloride-free fixed-dose combination of latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension
by: Bhagat P, et al.
Published: (2014)

Effect of benzalkonium chloride-free latanoprost ophthalmic solution on ocular surface in patients with glaucoma
by: Walimbe T, et al.
Published: (2016)

Results of case-control studies support the association between contact lens use and Acanthamoeba keratitis
by: Pacella E, et al.
Published: (2013)

Bimatoprost 0.01% or 0.03% in patients with glaucoma or ocular hypertension previously treated with latanoprost: two randomized 12-week trials
by: Myers JS, et al.
Published: (2014)

Utility of Ocular Motility Tests in Orbital Floor Fractures with Muscle Entrapment That is Not Detected on Computed Tomography
by: Migliorini R, et al.
Published: (2021)

A comfort comparison of travoprost BAK-free 0.004% versus latanoprost 0.005% in patients with primary open-angle glaucoma or ocular hypertension
by: David A Godfrey, et al.
Published: (2009)

Preservative-free tafluprost in the treatment of naive patients with glaucoma and ocular hypertension
by: Lanzl I, et al.
Published: (2013)

Preference for a fixed combination of brinzolamide/timolol versus dorzolamide/ timolol among patients with open-angle glaucoma or ocular hypertension
by: Sanseau A, et al.
Published: (2013)

Topical Medication Therapy for Glaucoma and Ocular Hypertension
by: Tao Wang, et al.
Published: (2021)

Comparison of clinical effects of two latanoprost 0.005% solutions (Xalatan® and Arulatan®) in primary open-angle glaucoma or ocular hypertensive patients: a randomized clinical trial
by: Brant Fernandes RA, et al.
Published: (2019)

Nanomedicine for glaucoma: liposomes provide sustained release of latanoprost in the eye
by: Natarajan JV, et al.
Published: (2012)

Correlation between ocular perfusion pressure and ocular pulse amplitude in glaucoma, ocular hypertension, and normal eyes
by: Figueiredo BP, et al.
Published: (2013)

Giant cell arteritis: the importance of immediate and appropriate diagnosis and treatment for better prognosis
by: Pacella F, et al.
Published: (2012)

Comparison of ocular surface assessment and adherence between preserved and preservative-free latanoprost in glaucoma: a parallel-grouped randomized trial
by: Dai Woo Kim, et al.
Published: (2021)

Clinical utility and differential effects of prostaglandin analogs in the management of raised intraocular pressure and ocular hypertension
by: Anne J Lee, et al.
Published: (2010)

Development of ocular hypertension and persistent glaucoma after intravitreal injection of triamcinolone
by: M Selim Kocabora, et al.
Published: (2008)

Clinical efficacy and neuroprotective effects of brimonidine in the management of glaucoma and ocular hypertension
by: Anna Galanopoulos, et al.
Published: (2008)

A study of the safety and efficacy of travoprost 0.004%/timolol 0.5% ophthalmic solution compared to latanoprost 0.005% and timolol 0.5% dosed concomitantly in patients with open-angle glaucoma or ocular hypertension
by: Douglas J Rhee, et al.
Published: (2008)

Preliminary results of an intravitreal dexamethasone implant (Ozurdex®) in patients with persistent diabetic macular edema
by: Pacella E, et al.
Published: (2013)

Blood pressure, ocular perfusion pressure and open-angle glaucoma in patients with systemic hypertension
by: Cantor E, et al.
Published: (2018)

Iris and periocular adverse reactions to bimatoprost in Japanese patients with glaucoma or ocular hypertension
by: Inoue K, et al.
Published: (2012)

Relationships between central corneal thickness and optic disc topography in eyes with glaucoma, suspicion of glaucoma, or ocular hypertension
by: Pinakin Gunvant, et al.
Published: (2008)

Efficacy and safety of combination therapy with latanoprost after a change in therapeutic regimen from timolol to brinzolamide in Japanese adult patients with primary open-angle glaucoma and ocular hypertension: open, non-randomized 12-week study
by: Shusaku Ishikawa, et al.
Published: (2008)

Administration of the fixed combination of latanoprost 0.005% and timolol 0.5% in glaucoma patients with an intraocular pressure over 30 mmHg
by: Yelda Buyru &Ouml;zkurt, et al.
Published: (2009)

Acquired color vision and visual field defects in patients with ocular hypertension and early glaucoma
by: Dimitris Papaconstantinou, et al.
Published: (2009)

Safety, tolerability, and efficacy of fixed combination therapy with dorzolamide hydrochloride 2% and timolol maleate 0.5% in glaucoma and ocular hypertension
by: Nicholas P Bell, et al.
Published: (2010)

Multicenter, prospective, open-label, observational study of bimatoprost 0.01% in patients with primary open-angle glaucoma or ocular hypertension
by: Laube T, et al.
Published: (2012)

Efficacy of preservative-free tafluprost in patients with normal-tension glaucoma previously treated with latanoprost
by: Sacchi M, et al.
Published: (2014)

Maximum Medical Therapy: Brinzolamide/Brimonidine And Travoprost/Timolol Fixed-Dose Combinations In Glaucoma And Ocular Hypertension
by: Lerner SF, et al.
Published: (2019)

Efficacy and safety of travoprost/timolol vs dorzolamide/timolol in patients with open-angle glaucoma or ocular hypertension
by: Miguel A Teus, et al.
Published: (2009)

Safety and tolerability of tafluprost in treatment of elevated intraocular pressure in open-angle glaucoma and ocular hypertension
by: Dorota Pozarowska
Published: (2010)

Incidence and Risk Factors of Ocular Hypertension/Glaucoma After Descemet Stripping Automated Endothelial Keratoplasty
by: Elalfy M, et al.
Published: (2021)

Efficacy and safety of travoprost alone or in combination with other agents for glaucoma and ocular hypertension: patient considerations
by: Emilio Rintaro Suzuki Jr, et al.
Published: (2010)

24-hour intraocular pressure in glaucoma patients randomized to receive dorzolamide or brinzolamide in combination with latanoprost
by: Yoshimi Nakamura, et al.
Published: (2009)

Latanoprost ophthalmic solution in the treatment of open angle glaucoma or raised intraocular pressure: a review
by: Andrea Russo, et al.
Published: (2009)

Update and optimal use of a brinzolamide-timolol fixed combination in open-angle glaucoma and ocular hypertension
by: Syed MF, et al.
Published: (2011)

Clinical appraisal of tafluprost in the reduction of elevated intraocular pressure (IOP) in open-angle glaucoma and ocular hypertension
by: Makoto Aihara
Published: (2010)